Large scale generation and validation of Aspegillus–specific T cells
Invansive aspergillosisrepresents a leading cause of morbidity and mortality in patients with hematological malignancies and hematopoietic stem cell /solid organ transplant recipients.Conventional antifungal drugs are often ineffective or/and associated with toxicity, they can lead to uncommon or drug-resistant molds, whereas theysignificantly increase the financial burden of transplant care.Adoptive immunotherapy withaspergillus-specific T cells (Asp-STs) constitutes an alternative and promising therapeutic approach against IA.
The aim of this project is the development and validation of a novel and simplified protocol to generate and scale up Asp-STs. Novelty relies on the development and delivery of an optimized and validated process which will replace the currenttime-consuming, laborious and costly, manufacturing procedures. The clinical translation of this research will be the management of invasive aspergillosis in immunocompromised patients with an advanced cell therapy over the conventional drug treatment.